F-10POS: Oncolytics Biotech Amends F-10 Registration Statements
Post-Effective Amendment to Registration Statement
Oncolytics Biotech Inc. has filed a post-effective amendment to its F-10 registration statements to revise the effectiveness date for the deregistration of unsold securities.
Summary
- Oncolytics Biotech Inc. has filed Post-Effective Amendment No. 2 to multiple Form F-10 registration statements.
- The primary purpose of this amendment is to revise the designated effectiveness date and time for the deregistration of securities that were not sold under these statements.
- The new effectiveness date for this action is set for April 8, 2026, at 4:30 p.m. Eastern time.
- This filing specifically addresses the withdrawal of unsold portions of securities registered under various previous registration statements dating back to 2007.
- No other changes have been made to the registration statements as previously amended.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, as it is purely administrative and does not provide new financial information or strategic updates.
Future Outlook
The filing does not contain forward-looking statements or guidance; it pertains to the administrative process of deregistering unsold securities.
Industry Context
StockSavvy.ai notes that this filing is primarily administrative, related to the winding down of previous registration statements for unsold securities, and does not reflect current operational or financial performance.
Stakeholder Impact
- Shareholders: No direct impact as this filing concerns unsold securities from past offerings and does not affect current outstanding shares or company operations.
Next Steps
- Deregistration of unsold securities under the specified registration statements will become effective on April 8, 2026.
Key Dates
| Date | Description |
|---|---|
| February 2, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 6, 2026 | Date of filing of Post-Effective Amendment No. 2 to the Registration Statements. |
| April 8, 2026 | Designated effectiveness date for the deregistration of unsold securities. |
Keywords
Oncolytics Biotech, SEC Filing, Form F-10, Registration Statement, Securities, Deregistration, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.